Dutch biotech firm Vico Therapeutics gathers $31m Series A

Vico Therapeutics, a Dutch biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, has raised $31 million in Series A financing.

Vico Therapeutics, a Dutch biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, has raised $31 million in Series A financing. The investors were Life Science Partners, Kurma Partners, Pontifax, Droia Genetic Disease, Polaris Partners, Pureos Bioventures and Idinvest Partners.

Source: Press Release